Luofang Biotechnology

Based in Shenzhen, China, Luofang Biotechnology (Polyncure) specializes in innovative high molecular therapies that aim to transform chronic disease management through advanced therapeutic solutions. Luofang Biotechnology, founded in 2025 and headquartered in Shenzhen, China, focuses on developing high molecular therapies for chronic health conditions. The company has completed one funding deal, with the most recent deal occurring on April 16, 2026, when it raised seed funding led by FountainBridge Capital, with participation from Darts Innovation Seed Fund. Polyncure specializes in innovative high molecular therapies aimed at transforming the future of chronic disease management.

The company focuses on developing advanced therapeutic solutions that leverage high molecular compounds to address various chronic health conditions. By employing cutting-edge technologies, Polyncure's products are designed to enhance the efficacy and delivery of treatments to patients, ultimately improving health outcomes. The company primarily targets healthcare providers, research institutions, and pharmaceutical partners as its client base, facilitating access to its novel therapies. Polyncure’s products are marketed not only in domestic markets but also strategically positioned in international markets, particularly in Asia and Europe, where there is a growing demand for advanced medical therapies.

Polyncure generates revenue through a structured transaction model that includes partnerships with healthcare organizations and pharmaceutical companies. This business model often involves collaborative agreements where the company provides its innovative therapeutic solutions in exchange for licensing fees or shared revenue from product sales. The pricing structure is designed to accommodate various client needs, with a focus on long-term partnerships that emphasize scalability and integration of their high molecular therapies into existing healthcare frameworks. While specific pricing plans for flagship products are not disclosed, the revenue streams are bolstered by ongoing collaborations and the potential for direct sales to healthcare providers.

This approach ensures that Polyncure remains positioned for sustained growth in the evolving healthcare landscape. In April 2026, Luofang Biotechnology raised an undisclosed amount of Seed funding, which will be utilized to advance preclinical research and IND applications for its first polymeric drug pipeline targeting cardiovascular calcification, alongside expanding the clinical translation of multiple chronic disease-related polymeric drug projects. The company plans to introduce new products designed to address chronic diseases, targeting specific international markets in Asia and Europe for expansion by 2027.